Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.57 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | CDC42 | P60953 | 1/20 | 0.57 |
| ▸ | RAC1 | P63000 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atb-346 SCHEMBL29358559 | 1.00 | PTGS2 (0.63) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| Atb-346 SCHEMBL31566275 | 1.00 | PTGS2 (0.63) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| Atb-346 SCHEMBL23643163 | 1.00 | PTGS2 (0.63) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| Atb-346 SCHEMBL29596141 | 1.00 | PTGS2 (0.63) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL30881594 | 0.90 | PTGS2 (0.66) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL29597190 | 0.90 | PTGS2 (0.66) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL2884705 | 0.90 | PTGS2 (0.66) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL14962625 | 0.89 | TDP1 (0.61) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL7712563 | 0.88 | TDP1 (0.75) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 | |
| SCHEMBL15929129 | 0.83 | AKR1C3 (0.45) | PTGS2TDP1L3MBTL1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025215470-A1 | AMORPHOUS OTENAPROXESUL FOR THE TREATMENT OF ACUTE PAIN | ANTIBE THERAPEUTICS, INC. (CA) | 2025-10-16 | — | — | WO | claimed |
| EP-4601632-A1 | AMORPHOUS OTENAPROXESUL AND COMPOSITIONS AND USES THEREOF AND DOSAGE REGIMENS FOR OTENAPROXESUL | Antibe Therapeutics Inc. (CA) | 2025-08-20 | — | — | EP | claimed |
| WO-2025076616-A1 | POLYMORPHIC FORMS OF OTENAPROXESUL AND COMPOSITIONS AND USES THEREOF | ANTIBE THERAPEUTICS INC. (CA) | 2025-04-17 | — | — | WO | claimed |
| WO-2024077386-A1 | AMORPHOUS OTENAPROXESUL AND COMPOSITIONS AND USES THEREOF AND DOSAGE REGIMENS FOR OTENAPROXESUL | ANTIBE THERAPEUTICS INC. (CA) | 2024-04-18 | — | — | WO | claimed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026089992-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260098098-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-2041108-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | Antibe Therapeutics Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008009118-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009118-A1 | 4-HYDROXYTHIOBENZAMIDE DERIVATIVES OF DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009127-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009127-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-24 | — | — | WO | disclosed |
| US-20080004245-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004245-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| US-20080004245-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ANTIBE THERAPEUTICS INC. (CA) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098098-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, CCR3, CCR1 | PTGS2 4756/4885TDP1 2442/4885L3MBTL1 171/4885 |
| US-20080004245-A1 | HYDROGEN SULFIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | PTGS1, HPGDS, PTGES | PTGS2 4/4885TDP1 4498/4885L3MBTL1 4088/4885 |
| US-20260116987-A1 | ANTIBODIES AND FUSION PROTEINS THAT BIND TO CCR8 AND USES THEREOF | CCR8, VSIG8, CCR3 | PTGS2 4788/4885TDP1 2928/4885L3MBTL1 302/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PTGS2 4318/4885TDP1 234/4885L3MBTL1 366/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | PTGS2 3466/4885TDP1 3810/4885L3MBTL1 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.